Hein Patrick A, Gladstone David J, Bellerive Marc R, Hug Eugen B
Section of Radiation Oncology, Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH 03756, USA.
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1540-8. doi: 10.1016/j.ijrobp.2005.04.013.
We selected five intraorbital tumor sites that are frequently found in clinical practice in children diagnosed with orbital rhabdomyosarcoma and performed three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated photon radiotherapy (IMRT) planning. Results of target coverage and doses to critical structures were compared. The goal of this study was to evaluate and to document realistic expectations as to organ-sparing capabilities of modern radiation therapy planning technologies with a focus on lens-sparing irradiation. Furthermore, we investigated potential added benefits of IMRT compared with 3D-CRT and the influence of protocol volume criteria definitions on the ability to obtain normal tissue dose sparing using the orbit as an example of a complex anatomic site.
The five intraorbital tumor sites were placed retrobulbar, temporal, nasal, in the upper inner and upper outer quadrant, the latter two more complex in shape. Gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV) were defined in image-fused computed tomography and magnetic resonance data sets. 3D-CRT and IMRT photon plans, using equal beam angles and collimation for direct comparison, were designed to 45 Gy prescription dose according to Intergroup Rhabdomyosarcoma Study Group-D9602 (IRSG-D9602) protocol (Intergroup Rhabdomyosarcoma Study V [IRS-V] protocol) for Stage I, Clinical Group 3 orbital rhabdomyosarcoma. To compare the impact of changed target definitions in IMRT planning, additional IMRT plans were generated using modified volume and dose coverage criteria. The minimum dose constraint (95%) of the PTV was substituted by a required minimum volume coverage (95%) with the prescribed dose. Dose-volume histograms (DVHs) were obtained, including target volumes, lens, optic nerves, optic chiasm, lacrimal gland, bony orbit, pituitary gland, frontal and temporal lobes.
Protocol target volume coverage criteria were fulfilled in all cases (5/5) with 3D-CRT and IMRT. Using the protocol criteria, lens sparing was achieved only for two tumor sites (retrobulbar and lateral position) with either planning technique. Mean lens doses were 8.5 and 10.4 Gy for 3D-CRT and 7.5 and 13.2 Gy for IMRT, respectively. The mean lens doses for the other three tumor locations averaged 26.8 Gy. IMRT plans reduced the lens dose in four of five cases by an average of 2.6 Gy compared with 3D-CRT. Modified target protocol prescription markedly reduced mean lens doses by 23-50% and by as much as 18 Gy. Recorded mean lens doses after protocol modification were 26% lower using IMRT plans compared with 3D-CRT. The cold spot as a result of the relaxed volume coverage requirements was within 2% of the original protocol criteria and located at the edge of the PTV, outside the CTV. Compared with 3D-CRT, IMRT resulted in an increase of brain volume receiving 10% (V10) and 20% (V20) of the prescribed dose.
Strict adherence to IRS-V protocol criteria prohibits at present lens sparing within compliance criteria for the majority of intraorbital tumor locations because of protocol-specific CTV and PTV target definitions. Changing protocol definitions by prescribing to the volume rather than to a dose constraint, IMRT planning significantly reduced lens doses. This was not accomplished to the same degree with 3D-CRT. Our study underlines the importance of appropriate selection of planning objectives to maximize the specific capabilities and advantages of IMRT in terms of sufficient target coverage and simultaneous sparing of critical structures. Our results can add to the ongoing discussion in the design of future 3D-CRT/IMRT protocols.
我们选取了在临床实践中儿童眼眶横纹肌肉瘤常见的五个眶内肿瘤部位,进行三维适形放疗(3D-CRT)和调强光子放疗(IMRT)计划。比较了靶区覆盖结果和关键结构的剂量。本研究的目的是评估并记录现代放射治疗计划技术在保留器官能力方面的实际期望,重点是保留晶状体的照射。此外,我们研究了IMRT与3D-CRT相比潜在的额外益处,以及方案体积标准定义对以眼眶这个复杂解剖部位为例获得正常组织剂量 sparing 能力的影响。
五个眶内肿瘤部位分别位于眼球后、颞部、鼻侧、上内象限和上外象限,后两个部位形状更复杂。在图像融合的计算机断层扫描和磁共振数据集中定义大体肿瘤体积(GTV)、临床靶体积(CTV)和计划靶体积(PTV)。根据横纹肌肉瘤协作组-D9602(IRSG-D9602)方案(横纹肌肉瘤协作组V [IRS-V]方案),针对I期临床3组眼眶横纹肌肉瘤,设计3D-CRT和IMRT光子计划,采用相等的射野角度和准直以便直接比较,处方剂量为45 Gy。为比较IMRT计划中靶区定义改变的影响,使用修改后的体积和剂量覆盖标准生成额外的IMRT计划。PTV的最小剂量约束(95%)被规定剂量的所需最小体积覆盖(95%)所替代。获得剂量体积直方图(DVH),包括靶区体积、晶状体、视神经、视交叉、泪腺、眼眶骨、垂体、额叶和颞叶。
3D-CRT和IMRT在所有病例(5/5)中均满足方案靶区体积覆盖标准。使用方案标准,仅在两个肿瘤部位(眼球后和外侧位置)采用任何一种计划技术时可实现晶状体保留。3D-CRT的平均晶状体剂量分别为8.5 Gy和10.4 Gy,IMRT的平均晶状体剂量分别为7.5 Gy和13.2 Gy。其他三个肿瘤部位的平均晶状体剂量平均为26.8 Gy。与3D-CRT相比,IMRT计划在五分之四的病例中使晶状体剂量平均降低了2.6 Gy。修改后的靶区方案处方使平均晶状体剂量显著降低了23% - 50%,多达18 Gy。方案修改后记录的平均晶状体剂量,IMRT计划比3D-CRT低26%。由于放宽体积覆盖要求导致的冷点在原始方案标准的2%以内,位于PTV边缘,CTV之外。与3D-CRT相比,IMRT导致接受10%(V10)和20%(V20)处方剂量的脑体积增加。
由于方案特定的CTV和PTV靶区定义,目前严格遵循IRS-V方案标准禁止在大多数眶内肿瘤部位的符合标准内保留晶状体。通过规定体积而非剂量约束来改变方案定义,IMRT计划显著降低了晶状体剂量。3D-CRT在相同程度上未实现这一点。我们的研究强调了适当选择计划目标的重要性,以在充分的靶区覆盖和同时保留关键结构方面最大化IMRT的特定能力和优势。我们的结果可补充到未来3D-CRT/IMRT方案设计的正在进行的讨论中。